VPC
Vestal Point Capital Portfolio holdings
AUM
$2.2B
1-Year Est. Return
36.26%
1 Year Est. Return
+36.26%
AUM
$2.2B
AUM Growth
+$305M
(+16%)
Holding
95
Top Buys
| 1 | +$84.9M | |
| 2 | +$79.5M | |
| 3 | +$56.2M | |
| 4 |
Repligen
RGEN
|
+$53.5M |
| 5 |
DexCom
DXCM
|
+$43.7M |
Top Sells
| 1 | +$203M | |
| 2 | +$124M | |
| 3 | +$123M | |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$92.3M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$79.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$13.5B
| $119M | 5.39% |
600,000
+400,000
|
|
||
2
Arcellx
ACLX
$4.16B
| $103M | 4.63% |
1,250,000
-1,500,000
|
|
||
3
Nuvalent
NUVL
$8.14B
| $95.1M | 4.3% |
1,100,000
+25,000
|
|
||
|
ABVX
4
Abivax
ABVX
$9.78B
| $84.9M | 3.83% |
+1,000,000
|
|
||
5
Alcon
ALC
$38.7B
| $82M | 3.7% |
1,100,000
+575,000
|
|
||
|
BCAX
6
Bicara Therapeutics
BCAX
$1.01B
| $80.5M | 3.64% |
5,100,000
+100,000
|
|
||
7
Amicus Therapeutics
FOLD
$3.26B
| $76.8M | 3.47% |
9,750,000
-2,150,000
|
|
||
8
Globus Medical
GMED
$11.6B
| $71.6M | 3.23% |
1,250,000
+750,000
|
|
||
9
Ionis Pharmaceuticals
IONS
$13.1B
| $70.3M | 3.18% |
1,075,000
+575,000
|
|
||
|
10
Jazz Pharmaceuticals
JAZZ
$10.2B
| $65.9M | 2.98% |
500,000
-700,000
|
|
||
11
Becton Dickinson
BDX
$57.3B
| $60.8M | 2.75% |
325,000
+300,000
|
|
||
12
Scholar Rock
SRRK
$4.78B
| $55.9M | 2.52% |
1,500,000
|
|
||
13
Immatics
IMTX
$1.35B
| $54.1M | 2.44% |
6,350,000
+100,000
|
|
||
|
14
Repligen
RGEN
$8.86B
| $53.5M | 2.41% |
+400,000
|
|
||
|
15
Dianthus Therapeutics
DNTH
$1.81B
| $46.4M | 2.1% |
1,180,000
-2,020,000
|
|
||
16
BioMarin Pharmaceuticals
BMRN
$10.2B
| $45M | 2.03% |
830,000
+330,000
|
|
||
17
Xenon Pharmaceuticals
XENE
$3.4B
| $44.2M | 1.99% |
1,100,000
-900,000
|
|
||
|
18
DexCom
DXCM
$26.1B
| $43.7M | 1.98% |
+650,000
|
|
||
19
Cytokinetics
CYTK
$7.75B
| $39.8M | 1.8% |
725,000
-2,250,000
|
|
||
20
Biogen
BIIB
$25.5B
| $38.5M | 1.74% |
+275,000
|
|
||
21
Cidara Therapeutics
CDTX
$6.94B
| $38.3M | 1.73% |
400,000
-100,000
|
|
||
22
Astria Therapeutics
ATXS
$738M
| $36.1M | 1.63% |
4,956,000
+434,000
|
|
||
23
Dyne Therapeutics
DYN
$2.75B
| $35.1M | 1.59% |
2,775,000
+2,047,500
|
|
||
24
Tyra Biosciences
TYRA
$1.21B
| $33.9M | 1.53% |
2,425,000
-230,000
|
|
||
25
Abbott
ABT
$218B
| $33.5M | 1.51% |
250,000
+75,000
|
|